Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott hails ‘important new JIA treatment’

Abbott hails ‘important new JIA treatment’

25th February 2008

Abbott has said that Humira (adalimuamb) is an important new treatment to reduce the signs and symptoms of moderate to severely active polyarticular juvenile idiopathic arthritis (JIA).

Humira is a compound that resembles naturally occurring antibodies found in the body that operates by blocking the inflammatory protein tumour necrosis factor alpha that is involved in the responses of some autoimmune conditions.

The drug received approval last week from the US Food and Drug Administration as a treatment for juvenile rheumatoid arthritis based on safety and efficacy results from recent clinical studies.

Humira has now received regulatory approval for the treatment of six diseases since 2002.

Daniel J Lovell, associate director in the division of rheumatology at Cincinnati Children’s Hospital Medical Centre, said: “Humira is an important new treatment that gives physicians and families another option that can ease the symptoms of polyarticular JIA.”

He added that the pain and inflammation caused by the disease can be debilitating in some children, making it difficult to engage in activities with other children, such as running, jumping and playing.

Last month, Abbott reported that recent regulatory approvals of Humira in patients with moderate to severe chronic plaque psoriasis offer patients with this condition a new treatment option.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.